NCT01518309已完成2 期
An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 39
- 主要终点
- Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)
研究概览
简要总结
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
pimavanserin tartrate (ACP-103)
Experimental
Tablets taken once daily by mouth at 20, 40, or 60 mg doses
干预措施: pimavanserin tartrate (ACP-103) (Drug)
结局指标
主要结局
Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)
时间窗: From first to last study drug dose plus 30 days
Number (%) of patients with drug-related treatment-emergent AEs
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03623321ACADIA Pharmaceuticals Inc.595
已完成
2 期
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's DiseaseAgitation and Aggression in Alzheimer's DiseaseNCT03118947ACADIA Pharmaceuticals Inc.79
终止
3 期
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentAdjunctive Treatment of Major Depressive DisorderNCT04000009ACADIA Pharmaceuticals Inc.235
已完成
早期 1 期
Pimavanserin Treatment in TSTardive DyskinesiaTourette SyndromeNCT04794413Joseph Jankovic10
终止
3 期
Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaSchizophreniaNCT03121586ACADIA Pharmaceuticals Inc.995